When performed together, the sensitivity of detection increases, and the survival advantage seen in the unmethylated group diminishes.93 These findings question the assumed benefit of temozolomide for all patients with glioblastoma and underscore the need for better diagnostics and treatment regimens since the current standard of care does not provide an advantage for MGMT-unmethylated patients. This evidence concerns the gene MGMT and glioblastoma.